General
Preferred name
TACROLIMUS
Synonyms
Envarsus ()
Vivadex ()
Perixis ()
Capexion ()
Tacrolimus Hydrate ()
Adoport ()
Tacni ()
Modigraf ()
Advagraf ()
FK506 ()
FR900506 ()
Fujimycin ()
FK 506 ()
Fujimycin monohydrate ()
FR900506 monohydrate ()
FK506 monohydrate ()
FK-506 ()
Tsukubaenolide ()
FK5 ()
Molecular-Glue ()
TACROLIMUS ANHYDROUS ()
Tacrolimus (monohydrate) ()
Tacrolimus (FK506) ()
FK506 (monohydrate) ()
Fujimycin (monohydrate) ()
FR900506 (monohydrate) ()
FK506, FR900506, Fujimycin, Prograf ()
NSC-758659 ()
Tacrolimus monohydrate ()
Prograf ()
FR-900506 ()
Protopic ()
Tacrolimus hydrate ()
Astagraf XL ()
Envarsus XR ()
P&D ID
PD003361
CAS
104987-11-3
109581-93-3
Tags
probe
natural product
drug
available
Drug Status
investigational
approved
withdrawn
Drug indication
Immunosuppressant
Organ transplant rejection
Ocular allergy
Max Phase
Phase 4
First approval
1994
Probe info
Probe type
experimental probe
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
2
No orthogonal probes found
Similar probes
1
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Tacrolimus is a macrolide antibiotic. It acts by reducing peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This inhibits both T-lymphocyte signal transduction and IL-2 transcription. Tacrolimus has similar activity to cyclosporine but rates of rejection are lower with tacrolimus. Tacrolimus has also been shown to be effective in the topical treatment of eczema, particularly atopic eczema. It suppresses inflammation in a similar way to steroids, but is not as powerful. An important dermatological advantage of tacrolimus is that it can be used directly on the face; topical steroids cannot be used on the face, as they thin the skin dramatically there. On other parts of the body, topical steroid are generally a better treatment.
DESCRIPTION
Tacrolimus acts as a calcineurin inhibitor and has immunosuppressive effects.
(GtoPdb)
MOA
FKBP-Tacrolimus inhibitor complex;Molecular Glue
INDICATION
For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was given FDA approval in 1994 for use in liver transplantation. Since then, this indication has expanded to kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
MOA
FKBP-Tacrolimus inhibitor complex, Molecular Glue
(Chemical Probes.org)
DESCRIPTION
inhibitor of calcineurin
(Informer Set)
DESCRIPTION
Dual site Src kinase inhibitor
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
5
Organisms
3
Compound Sets
28
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Chemical Probes.org
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
High-quality chemical probes
Informer Set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
66
Molecular Weight
803.48
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
3
Rotatable Bonds
7
Ring Count
4
Aromatic Ring Count
0
cLogP
4.64
TPSA
178.36
Fraction CSP3
0.77
Chiral centers
14.0
Largest ring
21.0
QED
0.18
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PPP3CA
PPP3CB
PPP3CC
PPP3R1
PPP3R2
FK506-binding protein 1A
FKBP-12
FKBP1A
Calcineurin inhibitor
antibiotic
Bacterial
FKBP
phosphatase
Autophagy,FKBP,phosphatase
Compound status
FDA
MOA
calcineurin inhibitor
Inhibitor
mTOR
FKBP12 gene modulator
Pathway
PI3K/Akt/mTOR signaling
Anti-infection
Apoptosis
Autophagy
Immunology/Inflammation
Metabolic Enzyme/Protease
Primary Target
Protein Ser/Thr Phosphatases
Member status
member
Indication
organ rejection
ATC
D11AX14
Target subclass
Immunophilin Protein Family
Immunophilin Protein Family
Therapeutic Class
Immunosuppressive Agents
Source data
